CryoCord Recognised by ASEAN Records for First and Most Mesenchymal Stem Cells Cultured by a Private Stem Cell Bank Laboratory

CryoCord Recognised by ASEAN Records for First and Most Mesenchymal Stem Cells Cultured by a Private Stem Cell Bank Laboratory

ASEAN Records is proud to officially recognise CryoCord for achieving:

First and Most Mesenchymal Stem Cells Cultured by a Private Stem Cell Bank Laboratory
(Storage service first launched 2009; MSC culturing commenced November 2008; 1.71 trillion MSCs cumulatively cultured as of November 2025)

This recognition celebrates CryoCord’s achievement in cumulatively culturing 1.71 trillion mesenchymal stem cells (MSCs) as of November 2025, reflecting more than 17 years of specialised laboratory work since commencing MSC cultivation in November 2008.

Culturing 1.71 Trillion Mesenchymal Stem Cells

Since beginning MSC cultivation in November 2008, CryoCord has developed its laboratory operations to support the processing and expansion of mesenchymal stem cells from different biological sources.

According to its cumulative laboratory records, CryoCord cultured 1,713,032.8 million MSCs, equivalent to approximately 1.71 trillion cells, as of November 2025.

This achievement represents the cumulative number of cells cultured over the recognised period, rather than the number of biological samples collected or stored, documenting the scale of CryoCord’s specialised laboratory activities.

Developing Stem Cell Culturing and Storage Capabilities Since 2008

CryoCord’s MSC cultivation activities commenced in November 2008, followed by the introduction of its mesenchymal stem cell storage services in 2009.

These services have included stem cells derived from umbilical cord tissue and other biological sources, supporting the company’s expansion beyond its original cord blood banking activities.

Through continued development of its laboratory facilities, technical processes and specialised workforce, CryoCord has established capabilities in cell processing, cryopreservation and emerging cell-based technologies.

Advancing Laboratory Standards and Biotechnology Research

Headquartered at the Bio-X Centre in Cyberjaya, Malaysia, CryoCord operates specialised laboratory facilities supporting stem cell processing, storage and research, with reported AABB accreditation and cGMP certification applicable to its laboratory operations.

Beyond stem cell banking, CryoCord has expanded its activities into mesenchymal stem cells, induced pluripotent stem cells, natural killer cells, CAR T-cell technologies and regenerative medicine research, reflecting its continued investment in scientific expertise and laboratory infrastructure.

The ASEAN Records recognition acknowledges CryoCord’s cumulative MSC cultivation achievement and its contribution to Malaysia’s growing biotechnology sector. The recognition relates specifically to cell cultivation volume and does not establish clinical treatment effectiveness.

A Milestone Moment of Recognition

ASEAN Records recognition was officially presented on 20 October 2026 at Hyatt Regency Kuala Lumpur at KL Midtown, during the 10th Gather of Achievers – ASEAN Records & ASIA Records Gala Night 2026.

The recognition was received on stage by James Then Khong Lek, Managing Director of CryoCord Group, representing CryoCord and its research, laboratory and operational teams whose collective contributions supported the achievement of cumulatively culturing 1.71 trillion mesenchymal stem cells.

Voices of Leadership

Reflecting on the recognition and CryoCord’s journey, James Then Khong Lek, Managing Director of CryoCord Group, shared:

“Receiving ASEAN Records recognition is a meaningful milestone for CryoCord and reflects the dedication of our scientists, laboratory specialists and team members throughout our development.

Since commencing mesenchymal stem cell cultivation in 2008, we have continued investing in scientific expertise, laboratory infrastructure and quality systems. Reaching 1.71 trillion cultured cells reflects years of consistent technical work and our commitment to advancing Malaysia’s capabilities in cell-based technologies.

This achievement encourages us to continue supporting responsible scientific research, strengthening collaboration with medical and academic institutions, and developing our expertise in emerging areas of cell and gene technology.”

About Cryocord

CryoCord Group is a Malaysian stem cell banking and cell-based biotechnology organisation established in 2002, headquartered at the Bio-X Centre in Cyberjaya, Selangor.

The company began with cord blood banking before expanding into mesenchymal stem cell cultivation and storage, immune cell banking, laboratory research and emerging cell and gene technologies. Its MSC cultivation activities commenced in November 2008, followed by the introduction of MSC storage services in 2009.

CryoCord’s development includes research and technical capabilities involving MSCs, induced pluripotent stem cells, natural killer cells, CAR T-cell technologies and related cell-processing applications. The group reports storing more than 70,000 biological samples and developing operations in Malaysia and Indonesia.

Through its continued focus on scientific research, laboratory standards and responsible technological development, CryoCord contributes to Malaysia’s biotechnology and cell and gene technology ecosystem.

For more information, visit:
https://cryocord.com.my/